Stocktwits on MSN

Novavax Stock Faces Retail Backlash As Shah Capital Warns Of Proxy Fight And Presses For A Sale

Shah Capital increased its stake to about 8.3% and said the gap between Novavax’s scientific potential and its commercial ...
TipRanks on MSN

Novavax’s Q3 2025 Earnings Call: Optimistic Outlook

Novavax (($NVAX)) has held its Q3 earnings call. Read on for the main highlights of the call. Novavax’s Q3 2025 Earnings Call: A Cautiously ...

Novavax Inc (NVAX) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Financial Challenges

Novavax Inc (NVAX) focuses on innovation and partnerships amid financial hurdles, aiming for profitability by 2028.

Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the third quarter ended ...
Shelton Herald

Novavax: Q3 Earnings Snapshot

GAITHERSBURG, Md. (AP) — GAITHERSBURG, Md. (AP) — Novavax Inc. (NVAX) on Thursday reported a loss of $202.4 million in its third quarter. On a per-share basis, the Gaithersburg, Maryland-based company ...

Novavax outlines $1.04B–$1.06B 2025 revenue framework and targets non-GAAP profitability as early as 2028 amid partnership-driven transition

Discover Novavax's Q3 2025 earnings: partnership-driven strategy, cost savings, increased revenue outlook, and pipeline progress.

Novavax raises annual revenue forecast on strength of vaccine deals

Novavax raised its annual revenue forecast for the third time this year on Thursday, banking on milestone payments from vaccine supply and licensing deals such as with Japan's Takeda Pharmaceuticals.